



Alan Milligan

Alan Milligan lives in London and works at the Royal Free Hospital. He comes from a military background, having trained in the British Army, and has served in the Light Infantry. He has worked in Emergency Care (A&E), Paediatrics and, for the last ten years, in Oncology and Haematology. Alan joined Dermatology at the Royal Free Hospital two years ago. He feels lucky to work with a great team that includes oncologist Dr David Chao, melanoma specialist and skin cancer lead for London Cancer.



Saskia Reeken

Saskia Reeken has worked for many years in Dermatology and Skin Cancer, gaining extensive experience initially as an Outpatients Sister and later CNS. After some years as Macmillan CNS Skin Cancer at St George's Hospital, she is currently employed at Kingston Hospital NHS Trust, facilitating services for skin cancer/dermatology patients. She is a founding board member for BASCSN (British Association of Skin Cancer Specialist Nurses) and actively works with other groups such as the London Cancer Alliance, Skin Cancer UK, Melanoma Task Force and NICE to take national skin cancer issues and education forward.

Thank you to our sponsors

The sponsors below have paid for stand space only and have had no other involvement in the arrangements for or content of this meeting.

Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.b-ms.co.uk.



MSD Oncology

Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At MSD Oncology, helping people fight cancer is our passion and supporting accessibility to our cancer medicines is our commitment. Our focus is on pursuing research in immuno-oncology and we are accelerating every step in the journey – from lab to clinic – to potentially bring new hope to people with cancer.



IGEA

Through extensive research, IGEA developed CLINIPORATOR™ for delivering electrochemotherapy, a minimally invasive treatment for cutaneous and subcutaneous metastases of melanoma and non-melanoma skin cancers. Electrochemotherapy has been recognised by NICE as an important treatment option for patients and clinicians where other treatment options may have been exhausted. IGEA is committed to improving patients' lives and treating them earlier in their disease.



Novartis Oncology



At Novartis Oncology, we are passionate about the discovery and development of innovative medicines. We seek to provide a broad range of new therapies, as well as practical solutions to advance the care of patients. Novartis Oncology has an extensive portfolio of 22 oncology, haematology and rare disease medicines treating more than 25 conditions, from breast and lung cancer to chronic myeloid leukaemia and acromegaly. Our broad pipeline includes 27 new molecular entities in development, targeting key molecular pathways in cancer biology. A decade of success in oncology drug development has taught us the value of our connections within the oncology community and their importance to innovation. Together, we explore novel compounds in clinical development, many with potential best-in-class status, aiming to meet unmet medical needs of cancer patients by advancing or creating new standards of care.

For more information visit www.novartis.co.uk

La Roche-Posay



For over 30 years, La Roche-Posay in France has worked with dermatologists throughout the world to develop skincare products that meet their standards and requirements. At the heart of the brand is the unique La Roche-Posay thermal spring water used in each and every skincare product. The efficacy of the water and suitability of our products for even the most sensitive skin are what differentiates the brand and give it its unquestionable credibility. Some 25,000 dermatologists worldwide recommend our skincare products to millions of women, men and children every day.

BASCSN 2015 ANNUAL CONFERENCE

Dear Colleague,

On behalf of the BASCSN Board, I am delighted to welcome you to the BASCSN Annual Conference and to Birmingham.

As you are aware, the role of the Skin Cancer Specialist Nurse is growing. While this has implications for our workload, it is also an exciting time to be practising in this area. After many years of what feels like little development, we are now able to offer our patients real hope in many areas of skin cancer, particularly melanoma.

Although we are busy professionals, it is important that we take the time to develop our skills and knowledge, network with colleagues, and share and discuss ideas. This conference is a great opportunity to do this – and also counts towards your CPD hours and NMC revalidation.

BASCSN is here to support you in your day-to-day practice and in your continuing development as a specialist nurse. It is your organisation, and the AGM (after lunch on 27 November) is an opportunity to tell us what you want from the Association.

Our sponsors make an important contribution to the meeting and we value their on-going support for BASCSN. I do hope you will visit their stands and have a chat.

Thank you for coming to Birmingham, I hope you enjoy the meeting.

Kind regards

Clair

Clair McGarr
BASCSN Chair



BASCSN

British Association of Skin Cancer Specialist Nurses



Hilton Garden Inn Hotel, Brindley Place, Birmingham

Programme

Thursday 26th November

17.00 - 19.00	Registration in hotel foyer
19.00 -19.30	Drinks reception in the Gallery (mezzanine floor)
19.30 -20.15	Living with melanoma • Dr Mark Sims
20.15	Dinner

Friday 27th November

From 6.30	Breakfast
08.00 - 09.00	Registration (mezzanine)
09.00 - 10.00	Advanced melanoma: latest developments and pathways to treatment Dr Neil Steven, Senior Lecturer and Honorary Consultant in Medical Oncology, University Hospitals Birmingham
10.00 - 10.30	Systemic treatments – managing side-effects Alice Tew, Senior Pharmacist, University Hospitals Birmingham
10.30 - 10.45	Discussion
10.45 - 11.15	COFFEE & EXHIBITION (ground floor)
11.15 - 11.45	Merkel cell carcinoma: clinical trial update Dr Neil Steven, Senior Lecturer and Honorary Consultant in Medical Oncology, University Hospitals Birmingham
11.45 - 12.30	Lymphoedema: current management Dr Kristiana Gordon, Consultant in Dermatology and Lymphovascular Medicine, St George's Hospital, London
12.30 - 13.00	The significance of sentinel lymph node biopsy results Dr Laszlo Igali, Consultant Histopathologist, Norfolk and Norwich University Hospital
13.00 - 14.00	LUNCH & EXHIBITION (ground floor)
14.00 - 14.30	BASCSN AGM - Have your say.
14.30 - 15.00	Living With & Beyond Cancer: health and well-being events Dr Natalie Doyle, Nurse Consultant Living With & Beyond Cancer, Royal Marsden Hospital, London
15.00 - 15.30	What do our patients say? The London Cancer Network patient experience survey Alan Milligan, CNS, Royal Free Hospital, London
15.30- 16.00	NICE guidelines: implications and implementation Saskia Reeken, CNS, Skin Cancer & Dermatology, Kingston Hospital, Surrey
16.00 - 16.30	Summary and close

Your Speakers



Mark Sims

Mark Sims is a Trust Grade SHO working in Emergency Medicine at Leicester Royal Infirmary. On 18 February this year he was admitted to Kingston Hospital with severe abdominal pain. He was subsequently diagnosed with stage 4 malignant melanoma, resulting from a primary tumour 11 years previously. Mark has extensive metastatic disease in his brain, liver, lung, spleen and gallbladder. He started a course of dabrafenib, a BRAF inhibitor, on his 27th birthday, and this significantly reduced his tumours. His disease is currently stable and he feels well. Mark has raised over £45 000 for Cancer Research UK, through sharing his powerful story on a Just Giving page (www.justgiving.com/mark-sims5) and, most recently, running the Leicester Half Marathon with his girlfriend, Georgie, and many other current and former Leicester medical students.



Neil Steven

Neil Steven is an Academic Consultant Oncologist at University Hospital and the University of Birmingham. He treats patients with advanced skin cancer, melanoma and Merkel cell carcinoma (MCC), seeking to offer access to trials and cutting-edge therapeutics where possible. He is a clinical trialist with translational expertise in early phase trials, rare cancers, immunotherapy for cancer and virus-associated malignancy. Neil is Clinical Lead for skin cancer trials for the West Midlands NIHR Clinical Research Network, a member of the NCRI Skin Cancer Clinical Studies Group and a member of the International Rare Cancers Initiative. He is national chief investigator for the Rational MCC trial, addressing uncertainty in treating primary MCC, and translational lead for the UKMMC01 trial, treating metastatic MCC.



Alice Tew

Alice Tew qualified as a pharmacist in 2002 and completed her Diploma in Clinical Pharmacy at the Royal United Hospital in Bath, before moving to the Queen Elizabeth Hospital, Birmingham ten years ago to specialise in Oncology. For the last five years Alice has taken the lead for oral chemotherapy within the Trust and, having worked across a wide variety of tumour sites, has developed a particular interest in renal cancer. Having qualified as a non-medical prescriber, she became involved in the hospital's melanoma clinic three years ago. Alice now works as part of the MDT within this clinic, counselling all new patients started on oral therapies and reviewing patients on treatment.



Kristiana Gordon

Kristiana Gordon is a Consultant in Dermatology and Lymphovascular Medicine. She is Clinical Lead of the Lymphoedema Service at St George's Hospital, London, where her team care for thousands of patients with primary and secondary lymphoedema from across the UK. Kristiana has recently completed her doctorate in the genetics of primary lymphoedema and imaging of the lymphatic system, but continues to pursue her research interests within the rapidly developing field of lymphovascular medicine.



Dr Laszlo Igali

Laszlo Igali is a practising histopathologist at the Norfolk and Norwich University Hospital, one of the UK's busiest departments, where he is the lead dermatopathologist. Laszlo's main research interests are skin and gastrointestinal cancer, and he introduced Mohs surgery and melanoma sentinel node biopsy at the hospital. He teaches general pathology at the University of East Anglia, is active in postgraduate training and is also a FRCPath examiner. Laszlo is dermatopathologist member for the Melanoma Guideline Group for NICE, and also a member of the NICE Innovation and Adoption panel. Other interests include health informatics, digital pathology and healthcare management.



Natalie Doyle

Natalie Doyle is Nurse Consultant for Living With & Beyond Cancer at the Royal Marsden NHS Foundation Trust in London, and co-chair of the Living With & Beyond Cancer (Survivorship) Committee. She leads on the practical implementation of the Recovery Package, a cluster of services and interventions designed to support and empower people following a diagnosis of cancer. In addition, Natalie leads the London Cancer Alliance (LCA) Survivorship Pathway Group, which is committed to facilitating the delivery of a comprehensive service for people living with and beyond cancer across the West and South of London, a population of over five million. As Immediate Past President of UKONS (United Kingdom Oncology Nursing Society), Natalie currently co-chairs the Cancer Nursing Partnership (CNP), a collaboration of organisations representing over 22 000 UK nurses and dedicated to the national implementation of the Recovery Package.